BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
2 Brivio P, Corsini G, Riva MA, Calabrese F. Chronic vortioxetine treatment improves the responsiveness to an acute stress acting through the ventral hippocampus in a glucocorticoid-dependent way. Pharmacological Research 2019;142:14-21. [DOI: 10.1016/j.phrs.2019.02.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
3 Kennedy SH, Avedisova A, Belaïdi C, Picarel-blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. European Neuropsychopharmacology 2016;26:378-89. [DOI: 10.1016/j.euroneuro.2015.09.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
4 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 7.2] [Reference Citation Analysis]
5 Choi S, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:629-38. [DOI: 10.1586/14737167.2016.1128830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
7 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
8 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
9 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
10 Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice 2017;21:13-23. [DOI: 10.1080/13651501.2016.1248852] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
11 Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord 2021;283:472-9. [PMID: 33516560 DOI: 10.1016/j.jad.2020.11.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, Zohar J, Mendlewicz J. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord 2018;227:777-86. [PMID: 29254066 DOI: 10.1016/j.jad.2017.11.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
13 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
14 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
15 Cao B, Xu L, Chen Y, Wang D, Lee Y, Rosenblat JD, Gao X, Zhan S, Sun F, McIntyre RS. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectr 2021;:1-9. [PMID: 33583460 DOI: 10.1017/S1092852921000171] [Reference Citation Analysis]
16 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
17 Culpepper L, Muskin PR, Stahl SM. Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. Am J Med 2015;128:S1-S15. [PMID: 26337210 DOI: 10.1016/j.amjmed.2015.07.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
18 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
19 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
20 Kennedy SH, Heun R, Avedisova A, Ahokas A, Olivier V, Picarel-blanchot F, de Bodinat C. Effect of agomelatine 25–50 mg on functional outcomes in patients with major depressive disorder. Journal of Affective Disorders 2018;238:122-8. [DOI: 10.1016/j.jad.2018.05.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
22 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Salagre E, Grande I, Solé B, Sanchez-moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:48-59. [DOI: 10.1016/j.rpsmen.2018.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
25 Bucki A, Marcinkowska M, Śniecikowska J, Więckowski K, Pawłowski M, Głuch-Lutwin M, Gryboś A, Siwek A, Pytka K, Jastrzębska-Więsek M, Partyka A, Wesołowska A, Mierzejewski P, Kołaczkowski M. Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. J Med Chem 2017;60:7483-501. [PMID: 28763213 DOI: 10.1021/acs.jmedchem.7b00839] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
26 Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-setälä M, Danchenko N, Koponen H, Kolasa K. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research 2017;17:293-302. [DOI: 10.1080/14737167.2017.1240617] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci 2015;17:111-26. [PMID: 26246787 [PMID: 26246787 DOI: 10.31887/dcns.2015.17.2/dionescu] [Cited by in Crossref: 61] [Article Influence: 12.2] [Reference Citation Analysis]
28 Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther Adv Psychopharmacol 2019;9:2045125319855206. [PMID: 31312426 DOI: 10.1177/2045125319855206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
30 Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother 2019;20:647-56. [PMID: 30759026 DOI: 10.1080/14656566.2019.1574747] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
31 El-Hage W, Fakra E. [How to treat and manage unsatisfactory response?]. Encephale 2016;42:1S39-47. [PMID: 26879256 DOI: 10.1016/S0013-7006(16)30018-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Baldwin DS, Hanumanthaiah VB. Vortioxetine in the treatment of major depressive disorder. Future Neurology 2015;10:79-89. [DOI: 10.2217/fnl.14.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
33 Azorin J, Adida M, Blin O, Simon N, Fakra E, Cermolacce M, Bottai T, Pringuey D, Micoulaud-franchi J, Belzeaux R, Kaladjian A. Comment le praticien doit-il interpréter les résultats d’un essai clinique ? L'Encéphale 2016;42:S26-9. [DOI: 10.1016/s0013-7006(17)30050-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018;33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;20:1142-50. [PMID: 26148812 DOI: 10.1038/mp.2015.92] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
36 Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders 2019;250:114-22. [DOI: 10.1016/j.jad.2019.03.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
37 Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. J Sex Med 2019;16:1638-49. [PMID: 31405765 DOI: 10.1016/j.jsxm.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
38 Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 2016;30:405-17. [PMID: 27113464 DOI: 10.1007/s40263-016-0334-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Kim Y, Lee YS, Kim MG, Song YK, Kim Y, Jang H, Kim JH, Han N, Ji E, Kim IW, Oh JM. The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events: a meta-analysis of randomized-controlled studies in depression. Int Clin Psychopharmacol 2019;34:9-17. [PMID: 30096056 DOI: 10.1097/YIC.0000000000000238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
40 Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S. Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. The World Journal of Biological Psychiatry 2019;20:427-48. [DOI: 10.1080/15622975.2019.1635270] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
41 Lee Y, Rosenblat JD, Lee J, Carmona NE, Subramaniapillai M, Shekotikhina M, Mansur RB, Brietzke E, Lee J, Ho RC, Yim SJ, Mcintyre RS. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review. Journal of Affective Disorders 2018;227:406-15. [DOI: 10.1016/j.jad.2017.11.003] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 17.7] [Reference Citation Analysis]
42 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
43 Brockbank J, Krause T, Moss E, Pedersen AM, Mørup MF, Ahdesmäki O, Vaughan J, Brodtkorb TH. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes 2021;19:94. [PMID: 33736649 DOI: 10.1186/s12955-021-01723-x] [Reference Citation Analysis]
44 Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2015;30:255-64. [PMID: 26020712 DOI: 10.1097/YIC.0000000000000081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, Wiles N. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 2019;12:CD010557. [PMID: 31846068 DOI: 10.1002/14651858.CD010557.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM, Katona C, Lewis G, Malizia A, McAllister-Williams RH, Ramchandani P, Scott J, Taylor D, Uher R; Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459-525. [PMID: 25969470 DOI: 10.1177/0269881115581093] [Cited by in Crossref: 309] [Cited by in F6Publishing: 247] [Article Influence: 51.5] [Reference Citation Analysis]
47 Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036-48. [PMID: 26331383 DOI: 10.1111/jsm.12980] [Cited by in Crossref: 45] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
48 Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. Journal of Psychiatric Research 2018;101:72-9. [DOI: 10.1016/j.jpsychires.2018.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
49 Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Rev Pharmacoecon Outcomes Res 2021;21:29-42. [PMID: 33307885 DOI: 10.1080/14737167.2021.1855979] [Reference Citation Analysis]
50 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
51 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Keks NA, Hope J, Culhane C. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Australas Psychiatry 2015;23:210-3. [DOI: 10.1177/1039856215581297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 François C, Nielsen R, Danchenko N, Williams V, Lançon C. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. Current Medical Research and Opinion 2017;33:1057-66. [DOI: 10.1080/03007995.2017.1299701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]